Dr. Chuanliang Cui 崔传亮
Chief Physician, Associate Professor
Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of melanoma, kidney cancer, and urothelial carcinoma of the bladder, ureter, or renal pelvis. Therapies include immunotherapy, molecular targeted therapy, and chemotherapy.
Dr. Cui holds a bachelor's degree from Shandong University School of Medicine (2002), a master's from Peking University Health Science Center (2005), and a doctoral degree in clinical oncology from Peking University Cancer Hospital (2012). Dr. Cui joined the hospital in 2005 and was a visiting scholar at the University of Pittsburgh Medical Center in 2010.
Name order: in Chinese the family name comes first (Cui Chuanliang). Papers usually list the name as Chuanliang Cui or Cui C.
Selected publications
130 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Immunol Res, 2026 (senior author): LM103, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced melanoma resistant to standard therapy. PubMed 42925158
- J Immunother Cancer, 2025 (senior author): Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights. PubMed 39915002
- J Immunother Cancer, 2024 (senior author): Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. PubMed 39366752
- Int J Radiat Oncol Biol Phys, 2024 (senior author): Efficacy and Safety of Postoperative Adjuvant Radiation Therapy in Resected Nasal Cavity and Paranasal Sinus Mucosal Melanoma: A Combined Analysis. PubMed 38522768
- Innovation (Camb), 2024 (first author): IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma. PubMed 38881798
- Immunotherapy, 2024 (senior author): SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma. PubMed 38197138
- Eur J Cancer, 2023 (senior author): Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial. PubMed 36753834
- BMC Cancer, 2023 (first author): Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. PubMed 36747118
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion